139 related articles for article (PubMed ID: 12605124)
1. An engineered bifunctional recombinant molecule that regulates humoral and cellular effector functions of the immune system.
Pizzolato MC; Fodor WL
Transplantation; 2003 Feb; 75(4):542-9. PubMed ID: 12605124
[TBL] [Abstract][Full Text] [Related]
2. CD86 blockade in genetically modified porcine cells delays xenograft rejection by inhibiting T-cell and NK-cell activation.
Costa C; Pizzolato MC; Shen Y; Wang Y; Fodor WL
Cell Transplant; 2004; 13(1):75-87. PubMed ID: 15040608
[TBL] [Abstract][Full Text] [Related]
3. Human NK cell-mediated cytotoxicity triggered by CD86 and Gal alpha 1,3-Gal is inhibited in genetically modified porcine cells.
Costa C; Barber DF; Fodor WL
J Immunol; 2002 Apr; 168(8):3808-16. PubMed ID: 11937533
[TBL] [Abstract][Full Text] [Related]
4. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
6. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
Pistillo MP; Tazzari PL; Bonifazi F; Bandini G; Kato T; Matsui T; Nishioka K; Conte R; Ferrara GB
Transplantation; 2002 Apr; 73(8):1295-302. PubMed ID: 11981425
[TBL] [Abstract][Full Text] [Related]
7. Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.
Vaughan AN; Malde P; Rogers NJ; Jackson IM; Lechler RI; Dorling A
J Immunol; 2000 Sep; 165(6):3175-81. PubMed ID: 10975832
[TBL] [Abstract][Full Text] [Related]
8. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
LaBelle JL; Hanke CA; Blazar BR; Truitt RL
Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization and applications of recombinant scFv antibodies to CD152 co-stimulatory molecule.
Pistillo MP; Tazzari PL; Ellis JH; Ferrara GB
Tissue Antigens; 2000 Mar; 55(3):229-38. PubMed ID: 10777098
[TBL] [Abstract][Full Text] [Related]
10. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
11. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
12. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells.
Huang JH; Tykocinski ML
Int Immunol; 2001 Apr; 13(4):529-39. PubMed ID: 11282992
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen.
Huang TH; Wu PY; Lee CN; Huang HI; Hsieh SL; Kung J; Tao MH
Blood; 2000 Dec; 96(12):3663-70. PubMed ID: 11090045
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
[TBL] [Abstract][Full Text] [Related]
16. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
[TBL] [Abstract][Full Text] [Related]
17. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
18. The interaction properties of costimulatory molecules revisited.
Collins AV; Brodie DW; Gilbert RJ; Iaboni A; Manso-Sancho R; Walse B; Stuart DI; van der Merwe PA; Davis SJ
Immunity; 2002 Aug; 17(2):201-10. PubMed ID: 12196291
[TBL] [Abstract][Full Text] [Related]
19. Intracellular capture of B7 in antigen-presenting cells reduces costimulatory activity.
Sheriff A; Vogt B; Baumgart M; Montag C; Hollenbach B; Schenk JA; Ulrich J; Elías F; Micheel B
Biochem Biophys Res Commun; 2003 Feb; 301(4):873-8. PubMed ID: 12589793
[TBL] [Abstract][Full Text] [Related]
20. CD80 expression is induced on activated B cells following stimulation by CD86.
Sahoo NC; Rao KV; Natarajan K
Scand J Immunol; 2002 Jun; 55(6):577-84. PubMed ID: 12028560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
